GPN Vaccines develops vaccines to protect adults and children from bacterial pathogens.

GPN Vaccines

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens.

Government of South Australia

National Health and Medical Research Council

Forepont Capital Partners

We are delighted to support Carla Gallasch as the University of Adelaide's first PhD student to be awarded a National Industry PhD Program Scholarship! 

Building on years of know how and learnings from the Gamma-PN program, Carla is working on a new vaccine to provide protection against Haemophilus influenzae - a major cause of ear infections in children.

GPN Vaccines is building its clinical team and is seeking an experienced Clinical Project Manager to work with our Chief Medical Officer. 

The role can be either full or part-time depending on experience and remote candidates are encouraged to apply. 

Industry experience is essential, and those with GCP training and a track record of running vaccine studies will be highly regarded.

Team lunches are getting bigger at GPN Vaccines! 

Celebrating the retirement of Professor James Paton and Leigh Willis who have both made invaluable contributions to the company, and welcoming new staff and students Chloe Gates, Ricky Williams, Brooke Dilmetz, Janice Henrichs and Mariana Couto Moniz.

We are pleased to announce the award of AUD$936,000 to GPN Vaccines in Round 3 of the CUREator Program! 

This funding will be used to support investigation of the durability of Gamma-PN's immune response in adults. 

Thank you to Brandon Capital and supporters CSIRO and Australian Government Department of Health and Aged Care for this important funding.

Congratulations Chloe Gates and welcome (officially) to the team! We look forward to building on the great work you did with us during your PhD as well as working on some exciting new projects!

We are humbled to have been invited to write a short review paper for Vaccine Insights recently titled 'Whole-cell pneumococcal vaccines: a future-proof approach to overcoming serotype replacement". 

Take a look if you are interested in learning more about our approach. 

Thanks for the opportunity BioInsights!

GPNV

COM:GPNVACCINES

GPN Vaccines

locale

market

industry

website

linkedin

founding date

competitor of

Metrics